Causal variant-targeted ribonucleic acid treatment for congenital melanocytic nevi Post author: Post published:June 19, 2024 Post category:uncategorized A genetic treatment targeting the causal NRAS c.181C>A mutation in congenital melanocytic naevus. You Might Also Like CHARMs: A new hope for prion disease therapy June 27, 2024 Tufts’ new ingestible microbiome sampling pill completes preclinical trials June 16, 2024 Stimulant users are caught in fatal ‘fourth wave’ of opioid epidemic January 3, 2025